Page last updated: 2024-08-26

mafosfamide and Carcinoma, Anaplastic

mafosfamide has been researched along with Carcinoma, Anaplastic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH1
Glüsenkamp, KH; Jähde, E; Rajewsky, MF1

Other Studies

2 other study(ies) available for mafosfamide and Carcinoma, Anaplastic

ArticleYear
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
    Journal of immunology (Baltimore, Md. : 1950), 1990, Dec-15, Volume: 145, Issue:12

    Topics: Animals; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; In Vitro Techniques; Interleukin-1; Kidney Neoplasms; Leukopenia; Lung; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neutropenia; Recombinant Proteins; Survival Analysis; Tumor Cells, Cultured

1990
Increased drug cytotoxicity at reduced pH counteracts cyclophosphamide resistance in cultured rat mammary carcinoma cells.
    International journal of cancer, 1989, Dec-15, Volume: 44, Issue:6

    Topics: Animals; Carcinoma; Cyclophosphamide; Drug Resistance; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Rats; Tumor Cells, Cultured

1989